Ionis gets a milestone approval; Another top FDA official to step down

5 days ago

The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to…

5 days ago

Novo’s next-gen obesity drug misses expectations in closely watched trial

Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the bar…

5 days ago

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair…

1 week ago

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from respiratory syncytial…

2 weeks ago

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that…

2 weeks ago

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing…

2 weeks ago

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to…

2 weeks ago

J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented…

3 weeks ago

The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide for weight…

3 weeks ago

The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas…